I am a
Home I AM A Search Login

Papers of the Week

2022 Jun 25

Expert Opin Investig Drugs

ALZT-OP1: An experimental combination regimen for the treatment of Alzheimer’s Disease.


Lozupone M, Berardino G, Mollica A, Sardone R, Dibello V, Zupo R, Lampignano L, Castellana F, Bortone I, Stallone R, Daniele A, Altamura M, Bellomo A, Solfrizzi V, Panza F
Expert Opin Investig Drugs. 2022 Jun 25.
PMID: 35758153.


For Alzheimer's disease (AD) treatment, US FDA granted accelerated approval for aducanumab due to its amyloid-β (Aβ)-lowering effects, notwithstanding the reported poor correlation between amyloid plaque reduction and clinical change for this drug. The diversification of drug targets appears to be the future of the AD field and from this perspective, drugs modulating microglia dysfunction and combination treatment regimens offer some promise.